Skip to content

Nasdaq · CIK 0001401040

DMAC DiaMedica Therapeutics Inc.

Insider trading from SEC Form 4. Last filing Jun 3, 2026. Close $8.33 on Oct 9, 2026, +56% from the 52-week low and -11% from the high.

DiaMedica Therapeutics Inc. (DMAC) has 35 SEC Form 4 filings on file from 14 insiders, the latest filed on Jun 3, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

5 open-market trades have been scored at DMAC. The newest: Jan Stahlberg (10% owner) bought $7.6M of stock on Nov 17, 2025, filed Dec 8, 2025, scored 35 (weak). The largest of the 5 shown: Thomas Von Koch (10% owner) bought $10.0M on Jul 23, 2025, scored 57 (moderate). 3 insiders bought within 14 days of each other around Jul 23, 2025.

DMAC closed at $8.33 on Oct 9, 2026, 56% above its 52-week low and 11% below its 52-week high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company

Price and insider trades, last year

DMACOct 9, 2026 · close 8.33

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at DiaMedica Therapeutics Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
35WeakJan Stahlberg
owner
buy
$7.6M
1,061,277 shares
+14%-
40ModerateJan Stahlberg
owner
buy
$6.0M
1,000,000 shares
+15%-
57ModerateThomas Von Koch
owner
buy
$10.0M
2,857,142 shares
+52%-
53ModerateJan Stahlberg
owner
buy
$5.4M
1,542,857 shares
+30%-
50ModerateRichard Jacinto II
owner
buy
$1.4M
400,000 shares
+9%-

Transactions

The newest 50 of 55 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Jun 1, 2026Daniel J. O'Connor
director
AGrant or award
Stock Option (right to buy)derivative
+40,412$0.00$040,412Jun 3, 2026
Jun 1, 2026Randall Michael Giuffre
director
AGrant or award
Stock Option (right to buy)derivative
+40,412$0.00$040,412Jun 3, 2026
Jun 1, 2026Julie Krop
Chief Medical Officer
AGrant or award
Stock Option (right to buy)derivative
+67,500$0.00$067,500Jun 3, 2026
Jun 1, 2026Dietrich John Pauls
President & CEO
AGrant or award
Stock Option (right to buy)derivative
+380,000$0.00$0380,000Jun 3, 2026
Jun 1, 2026Charles Pauling Semba
director
AGrant or award
Stock Option (right to buy)derivative
+40,412$0.00$040,412Jun 3, 2026
Jun 1, 2026Scott Kellen
CFO & Secretary
AGrant or award
Stock Option (right to buy)derivative
+162,000$0.00$0162,000Jun 3, 2026
Jun 1, 2026James T. Parsons
director
AGrant or award
Stock Option (right to buy)derivative
+51,189$0.00$051,189Jun 3, 2026
Jun 1, 2026Tanya Lewis
director
AGrant or award
Stock Option (right to buy)derivative
+40,412$0.00$040,412Jun 3, 2026
Jun 1, 2026Richard Kuntz
director
AGrant or award
Stock Option (right to buy)derivative
+40,412$0.00$040,412Jun 3, 2026
Jan 2, 2026Randall Michael Giuffre
director
AGrant or award
Common Stock
+6,175$8.42$52k398,587Jan 6, 2026
Jan 2, 2026Charles Pauling Semba
director
AGrant or award
Common Stock
+3,355$8.42$28k47,963Jan 6, 2026
Jan 2, 2026James T. Parsons
director
AGrant or award
Common Stock
+10,095$8.42$85k97,949Jan 6, 2026
Nov 17, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+187,393$6.52$1.2M7,951,858Dec 8, 2025
Nov 18, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+182,882$6.75$1.2M8,134,740Dec 8, 2025
Nov 19, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+240,352$7.21$1.7M8,375,092Dec 8, 2025
Nov 20, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+128,426$7.41$951k8,503,518Dec 8, 2025
Nov 21, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+208,872$7.41$1.5M8,712,390Dec 8, 2025
Nov 24, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+40,253$7.89$318k8,752,643Dec 8, 2025
Nov 25, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+73,099$8.57$627k8,825,742Dec 8, 2025
Nov 21, 2025James T. Parsons
director
MOption exercise
Common Stock
+12,000$2.20$26k87,854Nov 25, 2025
Nov 21, 2025James T. Parsons
director
MOption exercise
Stock Option (right to buy)derivative
-12,000$0.00$00Nov 25, 2025
Aug 11, 2025Julie Krop
Chief Marketing Officer
AGrant or award
Stock Option (right to buy)derivative
+450,000$0.00$0450,000Nov 3, 2025
Aug 13, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+293,601$5.91$1.7M7,058,066Sep 4, 2025
Aug 14, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+70,414$5.99$422k7,128,480Sep 4, 2025
Aug 15, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+8,233$6.00$49k7,136,713Sep 4, 2025
Aug 20, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+71,107$5.86$416k7,207,820Sep 4, 2025
Aug 21, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+48,172$5.96$287k7,255,992Sep 4, 2025
Aug 22, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+59,788$5.96$357k7,315,780Sep 4, 2025
Aug 25, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+338,265$6.00$2.0M7,654,045Sep 4, 2025
Aug 26, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+59,648$6.00$358k7,713,693Sep 4, 2025
Aug 27, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote
+50,772$6.00$305k7,764,465Sep 4, 2025
Jul 23, 2025Thomas Von Koch
owner
POpen-market purchase
Common Sharesindirect: See Footnote 1
+2,857,142$3.50$10.0M8,383,577Jul 25, 2025
Jul 23, 2025Jan Stahlberg
owner
POpen-market purchase
Common Sharesindirect: See Footnote 1
+1,542,857$3.50$5.4M6,764,465Jul 25, 2025
Jul 23, 2025Richard Jacinto II
owner
POpen-market purchase
Voting Common Shares, no par value per shareindirect: By Roth IRA
+400,000$3.50$1.4M4,958,823Jul 25, 2025
Jun 1, 2025Scott Kellen
CFO & Secretary
AGrant or award
Stock Option (right to buy)derivative
+225,000$0.00$0225,000Jun 3, 2025
Jun 1, 2025Richard Kuntz
director
AGrant or award
Stock Option (right to buy)derivative
+32,162$0.00$032,162Jun 3, 2025
Jun 1, 2025Tanya Lewis
director
AGrant or award
Stock Option (right to buy)derivative
+32,162$0.00$032,162Jun 3, 2025
Jun 1, 2025James T. Parsons
director
AGrant or award
Stock Option (right to buy)derivative
+40,739$0.00$040,739Jun 3, 2025
Jun 1, 2025Dietrich John Pauls
President & CEO
AGrant or award
Stock Option (right to buy)derivative
+600,000$0.00$0600,000Jun 3, 2025
Jun 1, 2025Charles Pauling Semba
director
AGrant or award
Stock Option (right to buy)derivative
+32,162$0.00$032,162Jun 3, 2025
Jun 1, 2025David J. Wambeke
Chief Business Officer
AGrant or award
Stock Option (right to buy)derivative
+250,000$0.00$0250,000Jun 3, 2025
Jun 1, 2025Randall Michael Giuffre
director
AGrant or award
Stock Option (right to buy)derivative
+32,162$0.00$032,162Jun 3, 2025
Apr 7, 2025Richard D. Pilnik
director
MOption exercise
Voting Common Shares, no par value per share
+24,000$2.11$51k312,995Apr 8, 2025
Apr 7, 2025Richard D. Pilnik
director
MOption exercise
Stock Option (right to buy)derivative
-24,000$0.00$00Apr 8, 2025
Feb 20, 2025Daniel J. O'Connor
director
AGrant or award
Stock Option (right to buy)derivative
+64,242$0.00$064,242Feb 24, 2025
Feb 13, 2025Randall Michael Giuffre
director
MOption exercise
Voting Common Shares, no par value per share
+12,000$2.11$25k387,412Feb 18, 2025
Feb 13, 2025Randall Michael Giuffre
director
MOption exercise
Voting Common Shares, no par value per share
+5,000$3.65$18k392,412Feb 18, 2025
Feb 13, 2025Randall Michael Giuffre
director
MOption exercise
Stock Option (right to buy)derivative
-12,000$0.00$00Feb 18, 2025
Feb 13, 2025Randall Michael Giuffre
director
MOption exercise
Stock Option (right to buy)derivative
-5,000$0.00$00Feb 18, 2025
Jan 2, 2025Charles Pauling Semba
director
AGrant or award
Voting Common Shares, no par value per share
+5,290$5.34$28k44,608Jan 3, 2025
50 of 55 rows shown.

Insiders

Everyone who has filed a Form 4 here.

Questions about DMAC

Answered from the filings on this page, as of the latest one.

Are insiders buying DMAC?

No. In the last 90 days no insider at DiaMedica Therapeutics Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade DMAC on the open market?

Jan Stahlberg (10% owner) bought $7.6M of DMAC on Nov 17, 2025 and filed the Form 4 on Dec 8, 2025. InsiderTell scored 35 (weak).

How many insiders file Form 4 at DiaMedica Therapeutics Inc.?

14 people have filed a Form 4 at DiaMedica Therapeutics Inc., among them Randall Michael Giuffre (director), Richard Jacinto II (10% owner), Scott Kellen (CFO & Secretary). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

DMAC insider trading: DiaMedica Therapeutics Inc. | InsiderTell